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Abstract
Background: Few studies have reported the dosage of cefmetazole (CMZ) for intraoperative antimicrobial
prophylaxis in patients underwent surgery for colorectal cancer. We therefore examined the optimal intraoperative
dosage of CMZ according to pharmacokinetic/pharmacodynamic (PK/PD) theory in patients who undergoing
surgery for colorectal cancer.
Methods: The study group comprised 23 patients with colorectal cancer who underwent surgery, using CMZ as
antimicrobial treatment to prevent postoperative infection. CMZ was administered intravenously within 60 min
before surgery. PK/PD analysis was performed by population pharmacokinetic analysis and Monte-Carlo simulation.
Results: The final population pharmacokinetic parameters of CMZ were as follows: CLCMZ = 0.0704 × creatinine
clearance (Ccr) and VdCMZ = 0.163 × body weight (Bw). In patients with a Ccr of ≥90 to <130 mL/min, the
probability of achieving concentrations exceeding MIC was 52.9 to 82.2% at 2 h after the initial dose and less than
20% at 3 h after the initial dose.
Conclusions: Additional doses of CMZ should be given every 2 h in patients with a Ccr of ≥90 to <130 mL/min,
every 3 h in those with a Ccr of ≥50 to <90 mL/min, and every 4 to 5 h in those with a Ccr of ≥10 to <50 mL/min.
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Background
Cefmetazole (CMZ) is a cephamycin’s antibiotics devel-
oped in Japan that has high antibacterial activity against
gram-negative and anaerobic bacteria. It is widely used
for antimicrobial prophylaxis (AMP) in patients under-
going lower gastrointestinal surgery [1].
Treatment schedules for AMP have been based on the
Centers for Disease Control and Prevention guidelines
[2], the recommendations of the Surgical Infection Pre-
vention Guideline Writers Workgroup meeting [3], and
recent collaborative guidelines issued by the American
Society of Health-System Pharmacists, the Infectious
Diseases Society of America, the Surgical Infection Soci-
ety, and the Society for Healthcare Epidemiology of
America [4]. A general consensus has also been reached
in Japan. However, very few studies have evaluated the
pharmacokinetics of CMZ during surgery for colorectal
cancer and reported the optimal intraoperative treat-
ment schedule for CMZ, including the timing of add-
itional doses.
We studied the pharmacokinetics of CMZ during sur-
gery in patients with colorectal cancer to determine the
optimal dosage of CMZ on the basis of pharmacokinet-
ics and pharmacodynamics.
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The study group comprised 23 patients who underwent
surgery for colorectal cancer and received CMZ for
AMP between November 2008 and December 2010. Pa-
tients who underwent emergency surgery, those with
ileus, and those who were receiving dialysis were
excluded.
As for the treatment schedule, 1 g of CMZ was intra-
venously administered over the course of 5 to 10 min
after the induction of anesthesia and within 60 min be-
fore the surgical incision. Subsequently, 1 g of CMZ was
additionally given every 3 h. In principle, blood samples
were collected at the start of surgery, on completion of
the anastomosis, immediately before additional doses of
AMP, and after abdominal closure.
Assay of cefmetazole concentrations
Serum CMZ concentrations were measured by high-
performance liquid chromatography (HPLC). After the
completion of surgery, blood samples were centri-
fuged at 3000 rpm for 10 min, and the serum super-
natant was preserved by freezing at −80 °C until
assay. At the time of assay, 200 μL of serum was com-
bined with 90 μL of a deproteinizing agent (1 M HClO4),
and the mixture was centrifuged at 1000 rpm and 4 °C for
5 min. The obtained supernatant was filtered through a
0.45-μm syringe filter, and 50 μL of the filtrate was
injected into a chromatograph. The HPLC column
temperature was 25 °C, with an ultraviolet absorption
wavelength of 256 nm. The mobile phase was prepared by
combining 800 mL of 50 mM phosphate buffer (pH 4.5)
with 200 mL of acetonitrile. The detection limit was
0.5 μg/mL.
Pharmacokinetics model
Population pharmacokinetic analysis of CMZ was per-
formed with the use of a nonlinear mixed effect model
(NONMEM) program (version VI, level 1.0). For the
pharmacokinetic model, we used predictions for popula-
tion pharmacokinetics (PREDPP) subroutines with a lin-
ear one-compartment model (ADVAN 1 and TRANS 2)
to estimate the pharmacokinetic parameters of the vol-
ume of distribution (VdCMZ) and clearance (CLCMZ).
The inter-individual variability of the pharmacokinetic
parameters was assessed using an exponential error
model according to the following eq (1):
Pj ¼ P  expðηjÞ ð1Þ
Where Pj is parameter value of the j-th subject, P is
the estimated population mean, and ηi is a random vari-
able with a mean of 0 and a variance of ω2.
The intra-individual variability of the parameters was
assessed using a proportional error model according to
the following eq (2):
Cij ¼ Cpred;ij  ð1þ εijÞ ð2Þ
Where Cij and Cpredij denotes observed and predicted
concentrations for the j-th subject at i-th time, and εis a
random intra-individual error which is normally distrib-
uted with mean 0 and variance σ 2.
Covariate analysis
The covariates of patients were performed for their in-
fluence on CMZ pharmacokinetic parameters as
followed; age (Age), gender (Gender), body weight (Bw),
Table 1 Demographic characteristics of the patients
Parameter Numbers Mean ± SD Range
Gender (male/female) 18 / 5
Cancer (colon / rectum) 14 / 9
Stage (I/II/III/IV) 10 / 6 / 6 / 1
Procedure (lapa / open) 13 / 10
Age (years) 69 ± 10 41–84
Body weight (kg) 63.7 ± 9.9 47.5–89.0
Body mass index (kg/m2) 24.1 ± 4.1 19.0–34.3
Serum creatinine (mg/dL) 0.84 ± 0.17 0.57–1.3
Creatinine clearance (mL/min) 73.9 ± 21.7 47.2–126.3
Serum albumin (g/dL) 3.8 ± 0.4 3.3–4.6
Operation time (min) 238 ± 73 140–430
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Fig. 1 Observed cefmetazole serum concentration from 23 patients.
The plots were showed after the first dose (●), the second dose (○),
and the third dose (▲)
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clinical pathological stage (Stage), serum creatinine
(Scr), creatinine clearance (Ccr), serum albumin (Alb),
and operative procedure (Procedure). Operative proce-
dures were divided into open surgery and laparoscopic
surgery. Ccr was calculated using the Cockcroft-Gault
equation.
The influence of continuous covariates on the pharma-
cokinetic parameter was modeled according to the fol-
lowing eqs (3, 4):
P ¼ θpþ θc ðcovarianceÞ ð3Þ
P ¼ θp θcðcovarianceÞ ð4Þ
The significance of the influence of covariates was
evaluated by the change of −2 log likelihood (the mini-
mum value of the objective function: OBJ).
Statistical significance was indicated by a p value of
<0.01. Only covariates providing a significant change in
the OBJ were included in the full model and were then
tested in a backward deletion step, with statistical signifi-
cance indicated by a p value of <0.001. The ability of the
final population pharmacokinetic model to describe ad-
equately the observed data was evaluated using visual
predictive values.
Model evaluation
Actual serum CMZ concentrations in individual patients
(Cp), predicted concentrations based on population pa-
rameters (PRED), and estimated individual predicted
concentration calculated by Bayesian fitting (IPRED)
were plotted to derive regression equations. Weighted
residual values for Cp and PRED were plotted to evalu-
ate the accuracy of serum concentrations estimated by
the final model.
Parameter precision and model stability were esti-
mated for the final model by the bootstrap method
[5].200 bootstrap samples were reconstructed, and the
final model was determined by the 200 bootstrap sam-
ples repeatedly tested. The mean and standard error
(S.E.) for each estimated parameters calculated normally
were compared with those obtained from the original
data set.
Evaluation of optimal dosage
A Monte-Carlo simulation [6] was performed 1000
times with the estimated and dispersion values of the
population pharmacokinetic parameters, using Microsoft
Excel 2010®. Estimated serum CMZ concentrations were
calculated after 2, 3, 4, 5, and 6 h. On the basis of the
minimum inhibitory concentration (MIC) distribution of
Bacteroides fragilis, the probability of achieving serum
CMZ concentrations above the MIC80 : MIC attainment
rate, was calculated. As for the MIC distribution of Bac-
teroides fragilis for CMZ, a Japanese surveillance report
Table 2 Hypothesis testing for fixed efects model on cefmetazole parameters
Parameter Fixed effects model OBJ - 2 l.l.d. p-value
CL θ1 491.305
θ1 + θ2 × Ccr 476.461 −14.844 0.001
θ1 + θ2 × 1 / Scr 486.958 −4.347 N.S.
θ1 × θ2Gender (Gender: male = 1, female = 0) 486.934 −4.371 N.S.
θ1; Age ≧ 65, θ2; Age < 65 491.291 −0.014 N.S.
θ1; Alb ≧ 3.8, θ2; Alb < 3.8 491.305 0 N.S.
θ1 + θ2 × (1 + (4 - stage)) 490.054 −1.251 N.S.
θ1 × θ2Procedure 491.074 −0.231 N.S.
θ1 + θ2 × BW 489.316 −1.989 N.S.
Vd θ1 × θ2Gender (Gender : male = 1, female = 0) 491.295 0.010 N.S.
θ1; Age ≧ 65, θ4; Age < 65 490.189 1.116 N.S.
θ1 + θ2 × BW 473.811 17.494 0.001
-2 l.l.d. : −2 log likelihood difference
N.S. Not significant
Table 3 Final pharmacokinetic parameter estimates for
cefmetazole in patients undergoing colorectal surgery
Pharmacokinetic Parameters
CLCMZ = θ1 × Ccr (L/h)
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of the antimicrobial susceptibility of clinical isolates of
anaerobic bacteria in 2004 was used.
Results
Table 1 shows the demographic characteristics of the pa-
tients. Serum concentrations were measured at a total of
86 points. The time course of serum CMZ concentra-
tions is shown in Fig. 1. Ccr was a covariate that signifi-
cantly influenced CLCMZ, and Bw was a covariate that
significantly influenced VdCMZ (Table 2). These factors
were integrated into the full model, which was compared
with a reduced model. Consequently, the final CMZ
population pharmacokinetic estimates were CLCMZ =
0.0704 × Ccr and VdCMZ = 0.163 × Bw. The calculated in-
terindividual variability (CV%) was 21.0% for CLCMZ and
8.4% for VdCMZ, and the residual variability was 13.5%
(Table 3).
On regression analysis of Cp and PRED, a correlation
coefficient of r2 = 0.8671 was obtained (Fig. 2a). On re-
gression analysis of Cp and IPRED, a correlation coeffi-
cient of r2 = 0.9437 was obtained (Fig. 2b). Weighted
residuals (WRES) estimated on the basis of Cp and
PRED were almost uniformly distributed within a range
of about ± 3 when WRES = 0 (Fig. 3). The results of
bootstrap validation of the estimated pharmacokinetic
parameters are shown in Table 4. The convergence rate
was 100% (200/200).
Table 5 shows the probability of attaining predicted
serum concentrations above the MIC of Bacteroides fra-
gilis : MIC target attainment rate, according to Ccr and
Bw, calculated on Monte Carlo simulation of the popula-
tion pharmacokinetic parameters. The MIC target at-
tainment rate 3 h after the initial dose of CMZ was 3.39
to 15.6% in patients with a Ccr of ≥90 to <130 mL/min,
57.9 to 81.5% in those with a Ccr of ≥50 to <90 mL/min,
and 96.0 to 96.7% in those with a Ccr of ≥10 to <50 mL/
min. The MIC target attainment rate at 2 h after the
initial dose of CMZ was 52.9 to 82.2% in patients with a
Ccr of ≥90 to <130 mL/min and 90% or higher in pa-
tients with a Ccr of 50 to <90 mL/min, irrespective of
Bw. In patients with a Ccr of ≥10 to <50 mL/min, the
MIC target attainment rate 5 h after the initial dose of
CMZ was 81.2 to 90.6%.
Discussion
Outside of Japan, cefoxitin and cefotetan are used as
perioperative antimicrobial prophylaxis in patients who
undergoing surgery for colorectal cancer [2–4]. Because
these drugs cannot be used in Japan, however, CMZ,
which is also a cephamycin’s antibiotics, is widely
employed. Few studies have examined the optimal dos-
age of CMZ in patients under surgery, including the
Fig. 2 a Relationship between observed concentration and predicted concentration based on population mean parameters using the Final
model (PRED). b Relationship between observed concentration and individual predicted concentration after Bayesian fitting (IPRED)
Fig. 3 Weighted residuals between observed concentration and
PRED (WRES) versus PRED
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intraoperative administration of additional doses. We be-
lieve that it is extremely important to assess the optimal
dosage of CMZ on the basis of PK/PD theory.
The CLCMZ obtained on population pharmacokinetic
analysis was dependent on Ccr, and VdCMZ was
dependent on Bw. These findings were considered rea-
sonable because more than 85% of CMZ is excreted as
the unchanged compound in the urine, and excretion is
mainly renal. A CLCMZ of 7.04 L/h (Ccr : 100 mL/min)
and a VdCMZ of 10.4 ± 1.6 L (Bw : 47.5 to 89.0 kg) were
generally consistent with the results of Borin et al. (CL :
6.96 L/h, Vd : 11.9 ± 4.2 L) [7] and Wong-Beringer et al.
(Vd : 0.14 to 0.28 L/kg) [8].
Finally, models were prepared for estimating CLCMZ
on the basis of Ccr, and VdCMZ on the basis of Bw.
These data can be obtained from serum chemical ana-
lysis before surgery, thus resulting in a clinically appro-
priate and practical model.
On diagnosis of the final model, regression analysis
showed that a high correlation coefficient was obtained
between observed serum CMZ concentrations and pre-
dicted CMZ concentrations based on population mean
parameters, with a high regression coefficient, suggesting
that predicted concentrations based on population mean
parameters were good. On bootstrap validation, the
mean bootstrap values approximated the final model
values. The robustness was 100% (200/200) on normal
completion of calculation, thus demonstrating the in-
ternal validity of the population parameters.
When the optimal treatment schedule for CMZ was
assessed using the obtained population pharmacoki-
netic parameters, the MIC attainment rate at 2 h
after initial treatment was 52.9 to 82.2% in patients
with a Ccr of ≥90 to <130 mL/min irrespective of
Bw. In contrast, the MIC attainment rate was less
than 20% at 3 h after initial treatment. This finding
suggested that additional doses should be given every
2 h after the initial dose in patients with a Ccr of
≥90 to <130 mL/min. Collaborative guidelines for
AMP published in 2013 [4] recommended that add-
itional doses of cefoxitin, a drug belonging to the
same category as CMZ, should be given every 2 h
after the initial dose in patients with normal renal
function. Therefore, the timing for additional doses of
CMZ in patients with a Ccr of ≥90 to <130 mL/min
is considered consistent with the recommendations of
current guidelines [3, 4].
However, the essential goal of AMP is to decrease bac-
terial counts to a level that does not cause infection,
given the susceptibility of the individual patient to infec-
tion. Therefore, treatment schedules should be adjusted
according to the Bw and renal function of individual pa-
tients, rather than indiscriminately giving additional
treatment to all patients.
Our results suggest that additional dose of CMZ
should be given every 2 h in patients with a Ccr of ≥90
to <130 mL/min, every 3 h to those with a Ccr of ≥50 to
<90 mL/min, and every 4 to 5 h in those with a Ccr of
≥10 to <50 mL/min. Our limitation was the low number
of renal failure (Ccr of <50 mL/min) patient (n = 1).
Therefore our recommended dosage should be adjusted
to each individual clinical situation and care must be
taken with patients to Ccr of <50 mL/min.
Further studies of larger number of patients are re-
quired to confirm whether our results are consistent
with external data and to assess the relation between
the MIC attainment rate and the risk of surgical site
infection.
Table 4 Bootstrap validation of the estimated pharmacokinetic parameters
Parameter Final modela (mean ± S.E.) Bootstrapb (mean ± S.E.) Differencec
θ1 (CL) 0.0704 ± 0.0029 0.0703 ± 0.0029 −0.001%
θ2 (Vd) 0.163 ± 0.0054 0.164 ± 0.0057 0.6%
ωCL 0.210 ± 0.0137 0.202 ± 0.0350 −3.8%
ωVd 0.084 ± 0.0053 0.070 ± 0.0377 −16.7%
σ 0.135 ± 0.0045 0.133 ± 0.0165 −1.5%
aObtained from the original data set
bCalculated from 200 bootstrap replications
c{(Bootstrap value - Final model value)/Final model value} × 100
Table 5 The target attainment rate above MIC80 of Bacteroides
fragilis calculated on Monte Carlo simulation
The target attainment rate
Bw (kg) Ccr (mL/min) 2 h 3 h 4 h 5 h 6 h
≧40 to 50
≧90 to <130 52.87% 3.39% 0.00% 0.00% 0.00%
≧50 to <90 91.24% 57.89% 19.42% 3.45% 0.37%
≧10 to <50 98.66% 96.67% 92.96% 81.20% 66.08%
≧50 to 60
≧90 to <130 72.44% 8.56% 0.14% 0.00% 0.00%
≧50 to <90 92.17% 72.40% 33.66% 8.28% 2.33%
≧10 to <50 98.19% 96.71% 93.43% 88.53% 74.18%
≧60 to 70
≧90 to <130 82.16% 15.57% 1.58% 0.00% 0.00%
≧50 to <90 92.69% 81.51% 44.25% 15.74% 4.78%
≧10 to <50 97.27% 96.06% 93.16% 90.56% 79.45%
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Conclusions
We studied to determine the optimal dosage of CMZ
during surgery in patients with colorectal cancer.
Our results suggest that additional dose of CMZ
should be given every 2 h in patients with a Ccr of ≥90
to <130 mL/min, every 3 h to those with a Ccr of ≥50 to
<90 mL/min, and every 4 to 5 h in those with a Ccr of
≥10 to <50 mL/min.
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